drugset / Trial / NCT07548671
Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).
Timeline
- Start
- 2026-04
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 3 mg/kg | — |
| Subject | Cyclosporine | Peptide | 5 mg/kg | — |
| Subject | Enarodustat | Small molecule | 8 mg | — |